Drugs / Ganfeborole
Ganfeborole
also known as
GSK3036656 · Ganfeborol · GSK-070 FREE BASE · GSK-3036656 FREE BASE · GSK-656 FREE BASE
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07784894 | Aug → Nov 2026 expected | tuberculosis | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT06354257 | Apr → Jul 2024 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03075410 | Apr → Aug 2017 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07773610 | Sep 2026 → Dec 2027 expected | pulmonary tuberculosis | TASK Applied Science | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05382312 | Jul 2022 → May 2025 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03557281 | Mar 2019 → Dec 2021 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-11-14 | GlaxoSmithKline | Results GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis gsk.com ↗
GSK3036656 doses of 5 mg to 30 mg showed bactericidal activity as evidenced by both endpoints after 14 days. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-14 | GlaxoSmithKline | GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis gsk.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ganfeborole | “GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacterium tuberculosis leucyl-tRNA synthetase.” PMID 38365949 ↗ Feb 2024 |
| Known as | Ganfeborol | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗ |
| Known as | GSK-070 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗ |
| Known as | GSK-3036656 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗ |
| Known as | GSK-656 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4116378 ↗ |
| Known as | GSK3036656 | “Ganfeborole (GSK3036656)” NCT05807399 ↗ |
| Action | Inhibit | “a leucyl-tRNA synthetase inhibitor” PMID 31182528 ↗ Jul 2019 |
| Modality | Small molecule | — CHEMBL4116378 ↗ |
| Route | Oral | “single and repeat oral doses of GSK3036656” PMID 31182528 ↗ Jul 2019 |